Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 348

Posts Tagged ‘trial’

Presentazione del “Rome Trial”

Posted by fidest press agency su mercoledì, 7 ottobre 2020

Roma mercoledì 14 ottobre 2020, ore 11 e 30 Rettorato Università La Sapienza. E’ uno studio innovativo assolutamente unico al mondo promosso dall’Istituto Superiore di Sanità, Università “La Sapienza” e Fmp – Fondazione per la medicina personalizzata. Intervengono Silvio Brusaferro, Presidente Istituto Superiore di Sanità, Eugenio Gaudio, Rettore dell’Università “La Sapienza di Roma, Paolo Marchetti, Presidente Fmp e direttore Oncologia Medica B del Policlinico Umberto I, professore ordinario di Oncologia Medica alla Sapienza e direttore del reparto di Oncologia Medica dell’Ospedale Sant’Andrea di Roma, Mauro Biffoni, Direttore del Dipartimento di Oncologia e Medicina Molecolare ISS.

Posted in Roma/about Rome, Università/University | Contrassegnato da tag: , , | 2 Comments »

Chair’s statement: MEP denied right to monitor a trial in Turkey

Posted by fidest press agency su giovedì, 20 febbraio 2020

Statement by the Chair of the European Parliament’s Delegation to the EU-Turkey Joint Parliamentary Committee.
Turkish authorities denied Member of the European Parliament Özlem Demirel (GUE/NGL, DE) the right to monitor a court hearing in Ankara. Sergey Lagodinsky (Greens/EFA, DE), the Chair of the European Parliament’s Delegation to the EU-Turkey Joint Parliamentary Committee, made the following statement:“It is unacceptable that my colleague Özlem Demirel was denied the right to monitor the court hearing. So far, such observation visits have been common practice in our bilateral cooperation. I consider the order to my second deputy in the EU-Turkey delegation, Ms Demirel, to leave the court building, a crude departure from our common practice, a provocation and a covert personal threat. I strongly condemn my colleague being treated in this way.Such incidents could further strain our bilateral parliamentary relations and ultimately destroy any remaining confidence in democratic culture in Turkey. The European Parliament and the German Federal Government must request a comprehensive clarification of the incident.”Özlem Demirel travelled to Turkey in her capacity as a Member of the European Parliament and as an international observer in order to support the families of the victims and to monitor the trial following the bombing of a peaceful demonstration on 10 October 2015.

Posted in Estero/world news, Politica/Politics | Contrassegnato da tag: , , | Leave a Comment »

Kingston Kicks off Security Drive Free Trial Campaign

Posted by fidest press agency su mercoledì, 23 agosto 2017

Kingston DTVP 3.0Kingston, the independent world leader in memory products, announced a free 21-Day trial program for its bestselling encrypted drive — DataTraveler Vault Privacy (DTVP) 3.0, targeted at selective organisations with bulk purchase needs in Australia. Launched in late 2013, DTVP 3.0 provides 100-percent hardware-based encryption to help enterprises safeguard business data and set security policies for end-users at an affordable price point, which makes it one of the hot-selling product lines among Kingston’s encrypted drives.Aiming to offer security IT professionals, small-to-medium businesses and corporate end users who require electronic data protection, Kingston now offers a great opportunity for said organisations in Australia to experience the reliability of its DTVP 3.0 USB Flash drive for free. The encrypted USB drive provides affordable business-grade security with 256-bit AES hardware-based encryption using XTS block cipher mode, and is available with optional, easy to deploy and easy to use (no installation required) anti-virus protection from ESET/ClevX that protects the drive’s contents from viruses, spyware, Trojans, worms, rootkits, adware and other Internet-borne threats.With bestselling encrypted drive DTVP 3.0, Kingston has a broad range of solutions designed for the highest levels of government use to enterprises and organisations of all sizes:
IronKey™ S1000 – the ultimate security encrypted USB Flash drive – is designed specifically to meet the strictest standards and most demanding data-protection needs of sensitive military, government and enterprise information. Capacities: 4GB, 8GB, 16GB, 32GB, 64GB, 128GB
IronKey D300 with optional Management – includes an advanced level of security that builds on the features that made IronKey well-respected in safeguarding sensitive information. Capacities: 4GB, 8GB, 16GB, 32GB, 64GB, 128GB
Since early 2016, Kingston has been the proud owner of the entire USB technology and assets of IronKey, a long-time leading brand in encrypted USB Flash drive solutions. Kingston continues the IronKey brand and tradition of delivering FIPS 140-2 Level 3 certified solutions to customers who need the highest level of encryption and security. With the IronKey brand, Kingston demonstrates its commitment as the global leader in trusted encrypted solutions for mobile data.DTVP 3.0, as well as Kingston’s full line of encrypted DataTraveler and IronKey USBs, is backed by a five-year warranty, free technical support and legendary Kingston reliability. Now is the best time to re-examine company security policies with professional help from Kingston. The free trial program is a limited time offer and only while supplies last. Terms and conditions apply. Visit http://kings.tn/dtvp30 for more information.Kingston Technology is the world’s largest independent manufacturer of memory products. Kingston designs, manufactures and distributes memory products for desktops, laptops, servers, printers, and Flash memory products for computers, digital cameras and mobile devices. Through its global network of subsidiaries and affiliates, Kingston has manufacturing facilities in California, Taiwan, China and sales representatives in the United States, Canada, Europe, Russia, Turkey, Ukraine, India, Taiwan, China, and Latin America. For more information, please visit http://www.kingston.com.Kingston and the Kingston logo are registered trademarks of Kingston Technology Corporation. All rights reserved. All other marks may be the property of their respective titleholders.

Posted in Economia/Economy/finance/business/technology, Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Gene therapy

Posted by fidest press agency su venerdì, 13 gennaio 2012

Evry (France)The results of a Phase I clinical trial of gene therapy for limb-girdle muscular dystrophy type 2C (a rare neuromuscular disease) have just been published in the journal Brain on January 11, 2012. The trial started in December 2006 and has been sponsored by Généthon (the not-for-profit research lab created by the French Muscular Dystrophy Association (AFM) and which is funded almost exclusively by donations from France’s annual Telethon). The trial at Pitié-Salpêtriere (AP-HP) is being led by principal investigators Professor Serge Herson (Head of the Department of Internal Medicine 1) and Professor Olivier Benveniste (Institute of Myology). The study’s primary objective was to evaluate the safety of local injection of increasing doses of an adeno-associated virus (AAV) vector harboring a “healthy” copy of the gene for gamma-sarcoglycan (the defective protein in this disease). Secondary objectives included the assessment of local and systemic immune reactions and the quality of gene transfer in the injected muscles in terms of efficacy, expression and distribution.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | 1 Comment »

Enrollment in First MRgFUS Essential Tremor Feasibility Trial Completed

Posted by fidest press agency su mercoledì, 4 gennaio 2012

English: Common effects of ionizing radiation ...

Image via Wikipedia

Tirat Carmel, Israel. InSightec Ltd, the global leader in MR guided Focused Ultrasound (MRgFUS) therapy, announced today that it has completed enrollment in the world’s first feasibility study evaluating the use of MRgFUS for treatment of Essential Tremor, using ExAblate® Neuro at University of Virginia , Charlottesville, Virginia. Fifteen patients underwent a non-invasive ExAblate treatment to evaluate safety and initial effectiveness of this investigational device. Most patients, who suffered for at least 10 years, experienced tremor improvement and no severe adverse events. They are being followed up for three months. Patient videos can be viewed here: http://bit.ly/sRpXno , http://bit.ly/tWaOl3ExAblate Neuro, pioneered by InSightec, combines high intensity focused ultrasound for deep accurate lesioning of the brain, with continuous realtime MR guidance for visualizing brain anatomy, planning and monitoring treatment and outcome. The lesioning is performed through an intact skull with no incisions or ionizing radiation. Additional research using MRgFUS for chronic neuropathic pain,targeted drug delivery, and sonothrombolysis for acute ischemic stroke is described in the January issue of Neurosurgical Focus devoted to MR guided focused ultrasound applications for central nervous system disorders.
Essential tremor, a very common movement disorder, affects millions of people worldwide. They have difficulty performing everyday tasks like drinking, eating, dressing, and writing. One third do not respond to medication, and may consider surgery. These have well recognized risks: high doses of ionizing radiation, complications and side effects from invasive surgery. MRgFUS was investigated as an alternative for these medically refractory patients.

Posted in Estero/world news | Contrassegnato da tag: , , , , | Leave a Comment »

Per evitare errori somministrazione farmaci

Posted by fidest press agency su venerdì, 15 ottobre 2010

Ancona 18 ottobre alle 12 Auditorium Montessori del Polo Murri di Torrette. Un illustre scienziato, il professor Silvio Garattini dell’Istituto di Ricerche Farmacologiche “Mario Negri” di Milano parlerà di “Bias nei trial clinici controllati”.
I Trial Randomizzati Controllati o RCT costituiscono gli studi clinici più potenti nella dimostrazione dell’efficacia di un intervento, sia esso un farmaco o un modello organizzativo o educativo. La loro forza è legata a come sono disegnati; nella forma più classica i soggetti affetti da una stessa malattia vengono casualmente (in maniera random) divisi in due gruppi: uno riceve il trattamento sperimentale, di cui si vuole dimostrare l’efficacia, e l’altro il trattamento di confronto (la terapia abituale per quella malattia o, in assenza di essa, un placebo) permettendo così di ottenere popolazioni omogenee per i possibili fattori confondenti noti e ignoti. I risultati di questo tipo di studi sono fondamentali per poter poi estendere le valutazioni su popolazioni più ampie di soggetti, determinando come risultato finale l’immissione in commercio di un farmaco, se è efficace, o il suo non-impiego in caso contrario.  Questi studi, sebbene considerati eccellenti rispetto a tutti gli altri esistenti, sono comunque gravati dalla possibile presenza di bias, vale a dire errori sistematici, che vengono commessi su tutti i soggetti arruolati. A esempio, il bias di selezione corrisponde a criteri di inclusione o esclusione dello studio troppo selettivi che portano a non considerare un numero alto di soggetti affetti dalla patologia considerata. Ma ne esistono altri ancora, di cui parlerà il professor Garattini.

Posted in Cronaca/News, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Adiponectina e la funzione cardiaca

Posted by fidest press agency su giovedì, 25 marzo 2010

Vari studi sembrano indicare che l’adiponectina possa essere connessa con la massa e la funzione del ventricolo sinistro (Lv), ma finora scarseggiavano sperimentazioni su campioni di dimensioni adeguate. Giungono ora i risultati di un trial del Karolinska Institutet di Stoccolma, volti a indagare tali associazioni in due ampie coorti di anziani. I ricercatori svedesi hanno valutato le relazioni trasversali tra l’adiponectina sierica e le misure ecocardiografiche di geometria e funzione cardiaca in 954 partecipanti di 70 anni d’età (50% donne) del Prospective investigation of the vasculature in Uppsala seniors (Pivus) e in 427 uomini di 71 anni d’età dell’Uppsala Longitudinal study of adult men (Ulsam). Nei modelli aggiustati per età, sesso, indice di massa corporea, pressione arteriosa sistolica, colesterolo Hdl, creatinina e fumo l’adiponectina è risultata inversamente associata con la frazione d’eiezione negli uomini, ma non nelle donne. Dopo aggiustamento addizionale per il peptide natriuretico cerebrale (NT-proBNP), l’associazione tra adiponectina e la frazione d’eiezione si è però attenuata. Dunque, le concentrazioni sieriche di adiponectina sono apparse effettivamente associate con la frazione d’eiezione negli uomini. «I nostri risultati» affermano gli studiosi «implicano che l’adiponectina possa essere associata con la funzione sistolica tramite vie metaboliche che coinvolgono i peptidi natriuretici». (fonte: doctor news)

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Homeopathy

Posted by fidest press agency su domenica, 7 marzo 2010

In a report published 22 February 2010, the Science and Technology Committee of  the United Kingdom House of Commons concludes that homeopathy is not efficacious (that is, it does not work beyond the placebo effect), that explanations for  why homeopathy would work are scientifically implausible and that further clinical  trials of homeopathy could not be justified. Furthermore, it concludes that the NHS should cease funding homeopathy and that the Medicines and Healthcare products Regulatory Agency (MHRA) should no longer license homeopathic medicines. Remarkably, just 4 of the 14 members of the Science and Technology Committee  voted on this report: 3 for, one against. One of its three signatories has stridently campaigned against homeopathy and continued to do so even in the period between  the hearings and the publication of the report. The European Committee for Homeopathy ECH and the International Homeopathic Medical League LMHI find the conclusions and recommendations of the Science and
Technology Committee completely unfounded. The report is highly tendentious and fundamentally flawed, consistently misrepresenting the scientific evidence to the  detriment of homeopathy and making unfounded and pejorative allegations against those who advocate or practise homeopathy. The report omits or misrepresents any evidence which challenges the view that homeopathy is a placebo response.  The report ignores large areas of evidence which were mentioned in written submissions and oral evidence such as systematic reviews and meta-analyses of  randomised controlled trials of homeopathy for specific conditions and groups of  conditions, and systematic reviews of biological models of homeopathic responses.  The evidence suggests that homeopathy is effective in a number of specific conditions, and there are a number of reproducible biological models of  homeopathy.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | 1 Comment »